rs3213094 — IL12B Promoter-region

IL12B Intronic Variant — Psoriasis Susceptibility and Ustekinumab Response Prediction

The IL12B gene¹¹ IL12B gene
located at 5q33.3, encodes the 40 kDa p40 subunit shared by two functionally distinct cytokines: IL-12 (p40/p35 heterodimer) and IL-23 (p40/p19 heterodimer). IL-12 drives Th1 differentiation and IFN-γ production; IL-23 expands Th17 cells and IL-17 production. Both pathways converge on psoriatic skin inflammation and inflammatory bowel disease. rs3213094 is an intronic variant at chr5:159323761 (GRCh38) within the IL12B gene, lying in strong linkage disequilibrium with the established IL12B regulatory haplotype. While earlier literature referred to this region loosely as "promoter-associated," dbSNP classifies rs3213094 as an intron variant (NM_002187.3:c.89-432G>T). Its significance lies not in direct protein change but in its tight linkage with regulatory elements that govern IL12B expression — and, crucially, in its independent value as a pharmacogenomic predictor of ustekinumab response²² pharmacogenomic predictor of ustekinumab response
Ustekinumab (Stelara) is a monoclonal antibody targeting the p40 subunit encoded by IL12B, blocking both IL-12 and IL-23 simultaneously.

The Mechanism

The T allele at rs3213094 tags a regulatory state of the IL12B locus associated with lower p40 expression. Genome-wide association studies in Chinese Han populations found the T allele to be protective against psoriasis (OR 0.78, combined p = 2.58×10⁻²⁶)³³ protective against psoriasis (OR 0.78, combined p = 2.58×10⁻²⁶)
Zhang et al., Nature Genetics 2009, first large Chinese psoriasis GWAS confirming IL12B as a major susceptibility locus, meaning the C allele is the risk-conferring allele. The protective T allele is associated with reduced IL12B transcriptional output in the regulatory environment defined by this haplotype block. This is pharmacogenomically consequential: individuals with one or two copies of the T allele have reduced baseline p40 availability, which changes the pharmacodynamic landscape for drugs targeting p40. For ustekinumab, the CT heterozygous genotype was associated with significantly better PASI reduction at 3 months compared to CC homozygotes in the Galluzzo 2016 study, suggesting that partial reduction of the IL12B risk-haplotype burden may allow ustekinumab to achieve more complete IL-12/23 pathway blockade.

The Evidence

The primary pharmacogenomic study is Galluzzo et al., Dermatology 2016⁴⁴ Galluzzo et al., Dermatology 2016
IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis, a retrospective Italian cohort of 64 patients treated with ustekinumab for up to one year. This study genotyped rs3213094 alongside rs2546890 and found that patients with the CT genotype at rs3213094 had significantly greater mean PASI reduction at 3 months compared to CC homozygotes (p = 0.017). The T allele was the favourable allele. The study also examined interactions with HLA-Cw6, the strongest single predictor of ustekinumab response, and found that IL12B genotype provided additional stratification beyond HLA-Cw6 status.

For psoriasis susceptibility, rs3213094 was confirmed in a two-stage Chinese Han GWAS⁵⁵ two-stage Chinese Han GWAS
Zhang et al. 2009, 1,139 cases + 1,132 controls discovery; 5,182 cases + 6,516 controls + 539 Uygur cases replication with a combined p-value of 2.58×10⁻²⁶ and an OR of 0.78 for the T allele — placing it among the most statistically robust SNPs at the IL12B locus. European studies of the IL12B haplotype report a complementary picture: the C allele (risk allele) confers elevated psoriasis odds across European populations, with estimates ranging from OR 1.4 to OR 1.9 depending on cohort and analysis model. A meta-analysis of 11 studies confirmed the IL12B risk haplotype in both psoriasis and psoriatic arthritis.

For inflammatory bowel disease, Brinar et al. 2013⁶⁶ Brinar et al. 2013
Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease found that IL12B variation was independently associated with need for early surgery within 5 years of Crohn's disease diagnosis, highlighting the shared pathogenic role of the IL12B locus across skin and gut inflammation. A meta-analysis of IL12B polymorphisms in IBD in Caucasian populations confirmed the association of the IL12B susceptibility haplotype with CD and UC risk.

Practical Actions

For individuals carrying the C allele (the risk genotype), two clinical contexts are most relevant. First, psoriasis susceptibility: the CC genotype marks elevated genetic risk for psoriasis and psoriatic arthritis through the same IL-12/23 axis that drives the condition. Second, and more immediately actionable, is biologic therapy planning: if ustekinumab is being considered for psoriasis or Crohn's disease, rs3213094 genotype provides independent pharmacogenomic information. The CT heterozygous genotype is associated with better early PASI response to ustekinumab; CC homozygotes appear to have attenuated benefit at 3 months, though response improves over longer treatment durations in many patients.

For individuals with one or two T alleles who develop psoriasis requiring biologics, this result supports ustekinumab as a rational first-line biologic choice — particularly in combination with HLA-Cw6 positivity, which additively improves response prediction. Guselkumab and risankizumab target only the p19 (IL-23-specific) subunit rather than the shared p40 encoded by IL12B, so their pharmacodynamic relationship with rs3213094 genotype differs from ustekinumab's.

Gut inflammation implications apply across genotypes: the IL12B locus's shared susceptibility with Crohn's disease and ulcerative colitis means carriers of the CC risk genotype with unexplained gastrointestinal symptoms warrant evaluation for subclinical IBD, mirroring the psoriasis-IBD comorbidity recognized in clinical practice.

Interactions

rs3213094 is in linkage disequilibrium with rs3212227 (3'-UTR IL12B) and rs6887695 (upstream IL12B), which together define the canonical IL12B psoriasis risk haplotype. Signals at rs3213094 and rs3212227 are not fully independent — they tag overlapping haplotype blocks — but rs3213094 has been studied as an independent pharmacogenomic marker for ustekinumab response (Galluzzo 2016), complementing the risk-susceptibility role of the haplotype SNPs. rs12188300 (also IL12B, near-gene regulatory) and rs3213094 together provide broader coverage of the IL12B susceptibility locus. rs11209026 (IL23R R381Q) is a protective loss-of-function receptor variant for IL-23; carrying both the IL12B CC risk genotype and IL23R protective A allele (rs11209026) creates a partially antagonistic combination where elevated p40 supply is partially offset by reduced receptor signaling downstream.